ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that the first patient in a clinical study examining the safety and effectiveness of an ST segment monitoring feature in an implantable cardioverter defibrillator (ICD) has been implanted with the investigational device in the United States. The ST Monitoring to Detect ACS Events in ICD Patients (Analyze ST) study will evaluate effectiveness of the feature in the Fortify® ST ICD by analyzing its accuracy in detecting acute coronary events, such as myocardial infarction, commonly known as a heart attack.
